Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Follicular Lymphoma
Clinical trial register · United States · industry-sponsored

Follicular Lymphoma Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 13 Florida 9 Kentucky 7 Illinois 6 North Carolina 6
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Follicular Lymphoma trials in the USA

21 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
NCT07634471Follicular Lymphoma
Merck Sharp & Dohme LLC
Phase 2/3
960
California, Kentucky, New Jersey, North Carolina, Tennessee
2026-06-22
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
Eli Lilly and Company
Phase 1
460
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Minnesota, New York
2026-04-17
Recruiting
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
NCT06794268Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Observational
300
Wisconsin
2025-02-04
Not yet open
Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research
NCT06049485Follicular Lymphoma
Power Life Sciences Inc.
Observational
500
California
2024-10
Recruiting
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06022029Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin
OncoNano Medicine, Inc.
Phase 1
168
California, Florida, Ohio, Pennsylvania, Texas, Virginia
2023-10-13
Recruiting
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
NCT05365659B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
Iksuda Therapeutics Ltd.
Phase 1
140
Maryland
2023-09-05
Active, closed
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
NCT05512390Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
AbbVie
Phase 1
39
Arizona, Florida, Minnesota, Nebraska, New York, North Carolina, Texas
2023-04-26
Active, closed
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
NCT05665062CLL/SLL, NHL, Mantle Cell Lymphoma, Follicular Lymphoma
Synthekine
Phase 1
36
California, New York, Ohio
2023-04-23
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Merck Sharp & Dohme LLC
Phase 2
189
Alaska, Arizona, Colorado, Illinois, Kansas, Kentucky, Maryland, Massachusetts
2022-07-21
Recruiting
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
NCT05255354Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma
Adaptive Biotechnologies
Observational
300
California
2022-06-01
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
BeOne Medicines
Phase 1/2
689
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2021-09-13
Recruiting
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
NCT04775745CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma
Newave Pharmaceutical Inc
Phase 1
60
North Carolina, Ohio, Utah
2021-07-19
Recruiting
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
NCT04669171Follicular Lymphoma, Marginal Zone Lymphoma
Enterome
Phase 1/2
80
Massachusetts, Minnesota, New York, Washington
2021-07-05
Active, closed
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052Follicular Lymphoma, Marginal Zone Lymphoma
Incyte Corporation
Phase 3
654
California, Connecticut, Florida, Georgia, Hawaii, Iowa, Kentucky, Louisiana
2021-04-15
Active, closed
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
NCT04594642B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
AstraZeneca
Phase 1
226
Florida, Kentucky, New Jersey, North Carolina, Ohio, Pennsylvania, Texas, Wisconsin
2021-03-02
Active, closed
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT04663347Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Genmab
Phase 1/2
543
Alabama, California, Massachusetts, Michigan, New Jersey, New York, North Carolina, Texas
2020-11-03
Active, closed
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
NCT04246086Follicular Lymphoma
Hoffmann-La Roche
Phase 1/2
237
California, Florida, Kentucky, Louisiana, Michigan, North Carolina, Ohio, Rhode Island
2020-08-12
Active, closed
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Epizyme, Inc.
Phase 3
599
Alabama, Arizona, California, Colorado, Florida, Illinois, Michigan, Minnesota
2020-06-11
Active, closed
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
NCT03600441Follicular Lymphoma
Xynomic Pharmaceuticals, Inc.
Phase 2
139
Illinois, Kentucky, New York, Pennsylvania, Texas, Washington
2018-08-27
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Janssen Research & Development, LLC
Phase 3
539
California, Connecticut, Georgia, Illinois, Indiana, Kansas, Kentucky, Massachusetts
2013-09-09
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/follicular-lymphoma

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 21 of those studies listing the condition Follicular Lymphoma.

How many Follicular Lymphoma trials are recruiting in the US?

10 of the 21 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Follicular Lymphoma), 21 studies
PhaseStudiesRecruitingShare
Phase 17433.3%
Phase 1/24219%
Phase 34119%
Observational3214.3%
Phase 2209.5%
Phase 2/3114.8%

Most active sponsors

Lead sponsors with the most studies (Follicular Lymphoma)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC21
AbbVie10
Adaptive Biotechnologies11
AstraZeneca10
BeOne Medicines11
Celgene11
Eli Lilly and Company11
Enterome11
Epizyme, Inc.10
Genmab10

Top states

Top states (Follicular Lymphoma), by number of studies with a site there
StateStudies
California13
Florida9
Kentucky7
Illinois6
New York6
North Carolina6
Arizona5
Georgia5
Massachusetts5
Ohio5
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.